DUBLIN--(BUSINESS WIRE)--The "Cell Viability Assays Market by Product (MTT Assay, XTT Assay, Calcein, Resazurin, Flow Cytometry, Spectrophotometer), Cell Type (Human, Animal, Microbial), Application (Basic Research, Stem Cell, Discovery & Development) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.
The cell viability assays market is expected to reach USD 4.16 billion by 2023 from an estimated USD 2.78 billion in 2018, at a CAGR of 8.4%.
The rising incidence and prevalence of chronic and infectious diseases, growing availability of funds for research and rising demand for cell-based assays in research, and increasing focus on the development of cell-based therapeutics are the key drivers for market growth. However, the high cost of instruments is expected to restrain the growth of this market to a certain extent during the forecast period.
On the basis of cell type, the cell viability assays market is segmented into human cells, animal cells, and microbial cells. The human cells segment is expected to register the highest CAGR during the forecast period. Growth in this segment is mainly due to the growing investments by government bodies and private sector organizations in research activities that are focused on developing new treatments for various human diseases.
On the basis of application, the cell viability assays market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications. The stem cell research applications segment is expected to witness the highest CAGR owing to the increasing number of stem cell research activities and rising investments in stem cell research.
North America is expected to account for the largest share of the global cell viability assays market in 2018. On the other hand, the APAC region is expected to witness the highest CAGR during the forecast period, owing to the increasing prevalence of chronic and infectious diseases in this region, large patient population, increasing healthcare spending, and growing interest of key players in APAC countries.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Cell Viability Assays Market, By Product
7 Cell Viability Assays Market, By Cell Type
8 Cell Viability Assays Market, By Application
9 Cell Viability Assays Market, By End User
10 Cell Viability Assays Market, By Region
11 Competitive Landscape
12 Company Profiles
- Abcam PLC
- Becton, Dickinson and Company
- Bio-Rad Laboratories
- Biotek Instruments
- Biotium
- Creative Bioarray
- Danaher Corporation
- GE Healthcare
- Merck KGaA
- Perkinelmer
- Promega Corporation
- Thermo Fisher Scientific